Spectrascience New Cash And Equivalents vs. Price To Earning
Based on the key profitability measurements obtained from Spectrascience New's financial statements, Spectrascience New may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Spectrascience New's ability to earn profits and add value for shareholders. At present, Spectrascience New's EV To Sales is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 228.44, whereas Operating Cash Flow Sales Ratio is projected to grow to (320.90). The current year's Change To Netincome is expected to grow to about 1.6 M, whereas Income Before Tax is forecasted to decline to (4.2 M).
Check out World Market Map. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.
For Spectrascience New profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spectrascience New to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spectrascience New utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spectrascience New's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spectrascience New over time as well as its relative position and ranking within its peers.
Spectrascience |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (0.92) |
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Spectrascience New Price To Earning vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth. Spectrascience New is currently regarded as top stock in cash and equivalents category among its peers. It also is currently regarded as top stock in price to earning category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spectrascience Price To Earning vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Spectrascience New |
| = | 27.88 K |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Spectrascience New |
| = | (0.04) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Spectrascience New Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spectrascience New, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spectrascience New will eventually generate negative long term returns. The profitability progress is the general direction of Spectrascience New's change in net profit over the period of time. It can combine multiple indicators of Spectrascience New, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Income Before Tax | -4 M | -4.2 M | |
| Net Loss | -4 M | -4.2 M | |
| Net Loss | -4 M | -4.2 M | |
| Operating Income | -2.8 M | -3 M | |
| Net Loss | -4 M | -4.2 M | |
| Total Other Income Expense Net | -780.7 K | -819.8 K | |
| Net Interest Income | -1 M | -1.1 M | |
| Change To Netincome | 1.5 M | 1.6 M | |
| Net Loss | (0.01) | (0.01) | |
| Income Quality | 0.39 | 0.37 | |
| Net Income Per E B T | 0.90 | 0.75 |
Spectrascience Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spectrascience New. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spectrascience New position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spectrascience New's important profitability drivers and their relationship over time.
Use Spectrascience New in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectrascience New position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectrascience New will appreciate offsetting losses from the drop in the long position's value.Spectrascience New Pair Trading
Spectrascience New Pair Trading Analysis
The ability to find closely correlated positions to Spectrascience New could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectrascience New when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectrascience New - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectrascience New to buy it.
The correlation of Spectrascience New is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectrascience New moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectrascience New moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectrascience New can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spectrascience New position
In addition to having Spectrascience New in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
To fully project Spectrascience New's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spectrascience New at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spectrascience New's income statement, its balance sheet, and the statement of cash flows.